Acura Pharmaceuticals Statistics
Total Valuation
Acura Pharmaceuticals has a market cap or net worth of 152,670. The enterprise value is 302,669.
| Market Cap | 152,670 |
| Enterprise Value | 302,669 |
Important Dates
The last earnings date was Friday, November 15, 2024.
| Earnings Date | Nov 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Acura Pharmaceuticals has 66.35 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 66.35M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 20.16% |
| Owned by Institutions (%) | 2.95% |
| Float | 9.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.08 |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.34 |
| EV / Sales | 0.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.72, with a Debt / Equity ratio of 1.12.
| Current Ratio | 0.72 |
| Quick Ratio | 0.43 |
| Debt / Equity | 1.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.07 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -58.46% |
| Return on Capital (ROIC) | -200.73% |
| Revenue Per Employee | 173,667 |
| Profits Per Employee | -97,667 |
| Employee Count | 9 |
| Asset Turnover | 1.20 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2,200.00% in the last 52 weeks. The beta is 49.58, so Acura Pharmaceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 49.58 |
| 52-Week Price Change | +2,200.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 70.51 |
| Average Volume (20 Days) | 2,785 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.83 |
Income Statement
In the last 12 months, Acura Pharmaceuticals had revenue of 1.56 million and -879,000 in losses. Loss per share was -0.02.
| Revenue | 1.56M |
| Gross Profit | 39,000 |
| Operating Income | -1.21M |
| Pretax Income | -879,000 |
| Net Income | -879,000 |
| EBITDA | -1.14M |
| EBIT | -1.21M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 65,000 in cash and 200,000 in debt, giving a net cash position of -135,000 or -0.00 per share.
| Cash & Cash Equivalents | 65,000 |
| Total Debt | 200,000 |
| Net Cash | -135,000 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 178,000 |
| Book Value Per Share | 0.00 |
| Working Capital | -143,000 |
Cash Flow
| Operating Cash Flow | -742,000 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 2.50%, with operating and profit margins of -77.67% and -56.24%.
| Gross Margin | 2.50% |
| Operating Margin | -77.67% |
| Pretax Margin | -56.24% |
| Profit Margin | -56.24% |
| EBITDA Margin | -73.00% |
| EBIT Margin | -77.67% |
| FCF Margin | n/a |
Dividends & Yields
Acura Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -75.75% |
| Shareholder Yield | -75.75% |
| Earnings Yield | -869.19% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on August 28, 2015. It was a reverse split with a ratio of 0.2.
| Last Split Date | Aug 28, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Acura Pharmaceuticals has an Altman Z-Score of -617.18. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -617.18 |
| Piotroski F-Score | n/a |